Many Bright Ideas Technologies Inc. (MBGNF)
OTC GREY OTC GREY Primary 
TSX-V Summary
Many Bright Ideas Technologies Inc. (MBGNF) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Many Bright Ideas Technologies Inc. ever had a stock split?
Many Bright Ideas Technologies Inc. Profile
| Professional Services Industry | Industrials Sector | Iain Weir-Jones CEO | OTC GREY Exchange | 565085107 CUSIP |
| CA Country | 7 Employees | - Last Dividend | 2 Jan 2018 Last Split | - IPO Date |
Overview
Many Bright Ideas Technologies Inc., formerly known as Med BioGene Inc., underwent a name change in June 2022 and had its origins rooted in the life science sector, specifically focusing on the development and commercialization of genomic-based tests for non-small-cell lung cancer. As of now, the company reports having no significant operations. Historically, its efforts were centered around the life sciences, but it has shifted its focus towards the commercialization of technologies across various industrial sectors. This strategic pivot signifies the company's departure from its original business model towards a broader technological commercialization approach. Many Bright Ideas Technologies Inc. was incorporated in 2006 and operates from its headquarters in Vancouver, Canada, reflecting its long-standing presence in the industry despite its recent transformations.
Products and Services
The provided information indicates that Many Bright Ideas Technologies Inc. currently does not have significant operations, rendering it challenging to outline specific products and services actively being commercially available. Historically, the company was engaged in the following area:
- Genomic-Based Tests for Non-Small-Cell Lung Cancer: The company was previously dedicated to the life sciences sector, with a particular emphasis on developing and commercializing genomic-based diagnostic tests aimed at non-small-cell lung cancer. These tests were designed to provide critical genetic information that could assist in the personalized treatment plans for patients suffering from this form of cancer.
With the company's shift in focus towards the commercialization of technologies in various industrial sectors, it is implied that Many Bright Ideas Technologies Inc. might explore new avenues and opportunities outside its original life science domain. However, specific products and services under this new direction have not been detailed, reflecting the company's current state of transitioning and seeking new operational areas.
